Skip to content
Bamboo Works
Search
Register / Sign in
MSCI China
|
MSCI China Small-Cap
|
Hang Seng Index
|
Hang Seng China Enterprise
  • Categories
    • IPO
    • Ecommerce
    • Finance
    • Social Media/Entertainment
    • Consumer
    • Education
    • Healthcare/biotech
    • New Energy
    • AI/Infrastructure/Resources
    • Property
    • China ESG Focus
  • Fast News
  • Expert Corner
  • Audio/Video
  • IPO
  • About
    • Who We Are
    • Our Writers
    • Partner with us
    • Contact Us
    • Join us
  • Eng
  • 简中
  • 繁中
Menu
  • Categories
    • IPO
    • Ecommerce
    • Finance
    • Social Media/Entertainment
    • Consumer
    • Education
    • Healthcare/biotech
    • New Energy
    • AI/Infrastructure/Resources
    • Property
    • China ESG Focus
  • Fast News
  • Expert Corner
  • Audio/Video
  • IPO
  • About
    • Who We Are
    • Our Writers
    • Partner with us
    • Contact Us
    • Join us

Pharmaron

Joinn Laboratories

Joinn’s ‘jumping’ monkey market hides core weakness

Despite announcing a sharp profit surge, the lab animal provider’s stock ticked up by just a muted 3% over the next three trading days Key Takeaways: Joinn Laboratories has built…
January 29, 2026
6127.HK
603127.SHG

WuXi AppTec Revenue Soars as Changing Government Policies Bring Headaches

The CXO giant announced it expects to post record-high revenue in the first quarter of 2022 Key takeaways: WuXi AppTec said it expects year-on-year revenue growth of 65% to 68%…
March 16, 2022

Newly Merged dMed-Clinipace Turns Up Heat in China’s Booming CRO Market

Company’s new $50 million funding is the first since its April merger, as competition grows among nation’s contract research organizations (CROs)   Key points: dMed-Clinipace’s raises $50 million in the…
July 29, 2021

Recent Articles

Joinn Laboratories
January 29, 2026

Joinn’s ‘jumping’ monkey market hides core weakness

6127.HK
603127.SHG
March 16, 2022

WuXi AppTec Revenue Soars as Changing Government Policies Bring Headaches

July 29, 2021

Newly Merged dMed-Clinipace Turns Up Heat in China’s Booming CRO Market

RELATED ARTICLES

  1. Ribo Life makes mRNA drugs
    January 2, 2026
    Hong Kong to welcome world-leading siRNA company as Ribo launches its IPO
  2. January 15, 2026
    InSilico lands drug discovery deal after Hong Kong IPO
    3696.HK
Discover hidden China stock gems in our weekly newsletter

Follow us

Facebook Twitter Linkedin Weixin Weibo Youtube

Subscribe to Our Free eNewsletter

Subscribe

Check out our content with some of our syndication partners

factiva

China stock insights and analysis for global investors: Bamboo Works unlocks investment opportunities in Chinese companies listed in the U.S. & Hong Kong.

  • About Us
  • Fast News
  • Audio/Video
  • Expert Corner
  • China ESG
Facebook Twitter Linkedin Weixin Weibo Youtube

Categories

  • New Energy
  • IPO
  • AI/Infrastructure/Resources
  • Education
  • Finance
  • Social Media/Entertainment
  • Consumer
  • Ecommerce
  • Healthcare/biotech
  • Property

Newsletter

Discover hidden China stock gems in our weekly newsletter
Copyright © 2021 - 2026 Bamboo Works. All rights reserved.